Ruxdentec Receives Breakthrough Device Designation

Here’s a breakdown of the provided text, summarizing the key information:

Main point:

Raludotatug deruxtecan, an investigational antibody-drug conjugate targeting CDH6, has received‍ Breakthrough Therapy Designation from the FDA for treating platinum-resistant epithelial ovarian cancer, primary peritoneal, or fallopian tube cancers expressing CDH6.

Key Details:

* What it is indeed: ⁢Raludotatug deruxtecan is a first-in-class CDH6-directed antibody-drug conjugate.
* Companies Involved: Developed by Merck and Daiichi Sankyo.
* Basis for Designation: The designation is based on data from two clinical trials:
* Phase 1 Trial: ⁢ Evaluated safety and efficacy in 179 adults with advanced ovarian cancer previously treated with platinum-based chemotherapy and a ⁢taxane. Focused on determining the maximum tolerated dose and assessing safety in ovarian and renal cell carcinoma patients.
* ⁢ REJOICE-Ovarian01 (Phase 2/3 Trial): A larger trial involving approximately ⁤710 ⁣patients⁣ with platinum-resistant ovarian ⁢cancer.
* Phase 2: Determining the⁣ optimal dose (4.8mg/kg, 5.6mg/kg, or‍ 6.4mg/kg) based on objective response ‍rate (ORR).
* Phase 3: Comparing raludotatug deruxtecan to investigator’s choice‍ of chemotherapy, with ORR and progression-free survival (PFS) as primary endpoints.
* Importance: Patients with platinum-resistant ovarian cancer have⁣ limited treatment options, making this a possibly important new therapy.

Quote:

Ken ‍Takeshita, MD (Daiichi Sankyo), emphasized the urgent need for new medicines to improve outcomes for patients with platinum-resistant ovarian cancer.